===============================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________________________
DATE OF REPORT: May 28, 2002
DATE OF EARLIEST EVENT REPORTED: May 24, 2002
ICN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 1-11397 33-0628076
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification
Number)
3300 HYLAND AVENUE
COSTA MESA, CALIFORNIA 92626
(Address of principal executive offices)
Registrant's telephone number, including area code: (714) 545-0100
===============================================================================
Item 5. Other Events.
------------
On May 24, 2002, Jean-Francois Kurz resigned from the Board of
Directors of ICN Pharmaceuticals, Inc. (the "Company"). The Board
of Directors appointed Norman Barker, a current director whose
term expires at the Company's 2003 Annual Meeting of
Stockholders, to fill the vacancy. Mr. Barker will serve the
remainder of Mr. Kurtz term which expires at the Company's 2003
Annual Meeting of Stockholders. Mr. Kurz will remain a director
of ICN International. Mr. Kurz's resignation is consistent with
the Company's restructuring plan which contemplates that each of
the Boards of ICN Americas, ICN International and Ribapharm will
have separate, independent directors.
Item 7. Financial Statements and Exhibits
---------------------------------
None.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on behalf of
the undersigned hereunto duly authorized.
Dated: May 28, 2002
ICN PHARMACEUTICALS, INC.
By: /s/ Gregory Keever
----------------------------
Name: Gregory Keever
Title: Executive Vice President,
General Counsel and
Corporate Secretary